These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 19060425

  • 1. Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
    Kurabayashi M, Yamazaki T, SUBARU Study Group.
    J Atheroscler Thromb; 2008 Dec; 15(6):314-23. PubMed ID: 19060425
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
    Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, Miller P, Palmer M, Sosef F, POLARIS study investigators.
    Atherosclerosis; 2007 Oct; 194(2):e154-64. PubMed ID: 17229426
    [Abstract] [Full Text] [Related]

  • 3. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
    Shioji K, Izuhara M, Mitsuoka H, Uegaito T, Matsuda M, Kishiwada Atherosclerosis Prevention Study (KAPS) Group.
    Cardiovasc Ther; 2014 Jun; 32(3):97-104. PubMed ID: 24456217
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 9. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.
    Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS, Kim KY, Jeong MH, Chae JK, Oh SK, Seong IW.
    Korean J Intern Med; 2010 Mar; 25(1):27-35. PubMed ID: 20195400
    [Abstract] [Full Text] [Related]

  • 10. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
    Davidson M, Ma P, Stein EA, Gotto AM, Raza A, Chitra R, Hutchinson H.
    Am J Cardiol; 2002 Feb 01; 89(3):268-75. PubMed ID: 11809427
    [Abstract] [Full Text] [Related]

  • 11. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
    Mazza F, Stefanutti C, Di Giacomo S, Vivenzio A, Fraone N, Mazzarella B, Bucci A.
    Am J Cardiovasc Drugs; 2008 Feb 01; 8(4):265-70. PubMed ID: 18690760
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG.
    Am J Cardiol; 2003 Mar 06; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/l in high cardiovascular risk patients (ARIANE study)].
    Danchin N, Chadarevian R, Gayet JL, Licour M, Valensi P.
    Ann Cardiol Angeiol (Paris); 2007 Apr 06; 56(2):82-7. PubMed ID: 17484092
    [Abstract] [Full Text] [Related]

  • 19. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
    Ballantyne CM, Raichlen JS, Cain VA.
    J Am Coll Cardiol; 2008 Aug 19; 52(8):626-32. PubMed ID: 18702965
    [Abstract] [Full Text] [Related]

  • 20. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
    Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J.
    Am J Cardiol; 2012 May 01; 109(9):1239-46. PubMed ID: 22360820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.